Research progress of chimeric antigen receptor T cells therapy in hematological malignancies
10.3760/cma.j.cn112309-20210520-00167
- VernacularTitle:嵌合抗原受体T细胞治疗血液肿瘤的研究进展
- Author:
Tong XU
1
;
Hui LIU
Author Information
1. 北京医院血液内科 国家老年医学中心 中国医学科学院老年医学研究院 100730
- Keywords:
Chimeric antigen receptor T cell;
Hematologic malignancies
- From:
Chinese Journal of Microbiology and Immunology
2021;41(7):560-564
- CountryChina
- Language:Chinese
-
Abstract:
From the first time that lymphokine active killer(LAK) cell , were induced in 1982, to the first chimeric antigen receptor T-cell (CAR-T) immunotherapy was used by Dr. Rosenberg in 2010 to successfully treat chronic lymphocytic leukemia (CLL), and Novartis′ CAR-T therapy Kymriah is approved by the FDA for B-lineage acute lymphoblastie leukemia (B-ALL) in 2017, CAR-T immunotherapy has entered a new era. The pipeline of CAR-T therapy is rapidly expanding, including the exploration of new targets. In addition to the research focus on CD19, CD20, CD22 and B cell maturation antigen(BCMA), new research directions such as dual targets, gene edited CAR-T are also constantly advancing. Compared with solid tumors that are limited by factors such as tumors microenvironment, CAR-T immunotherapy has more obvious effects in the field of hematological malignancies, such as the FDA approved CAR-T therapy Yescarta, Kymriah, Tecartus, Breyanzi and Abecma. This article will review the recent research progress of clinical treatment in hematological malignancies.
